OncoMatch/Clinical Trials/NCT06145074
Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.
Is NCT06145074 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Propranolol for pancreatic cancer.
Treatment: Propranolol — The IMPULS trial is a randomized, triple-blinded, placebo controlled, single center, pilot trial examining the efficacy and safety of preoperative propranolol in patients scheduled for pancreatic cancer surgery. The study is conducted as a type 1 hybrid efficacy-implementation trial of 30 patients. This study is designed to provide pilot data for a future larger perioperative study of propranolol with the aim of improving outcomes for pancreatic cancer surgery. In total, 30 participants will be allocated in a 1:1 ratio with 15 participants enrolled in each trial arm (propranolol vs. placebo). Participants will be allocated to either 40 mg propranolol twice daily or placebo twice daily in 10 days prior to planned surgery. Primary outcomes: Evaluating the efficacy of preoperative propranolol on anxiety and in pro-tumorigenic changes (e.g., in the tumor tissue and in blood samples) in patients undergoing surgery for pancreatic cancer. Furthermore, to obtain follow up data (e.g., 90-day mortality, postoperative complications etc. on the patients receiving propranolol versus placebo). Heart rate variability among the participants will also be examined. Secondary: Examining the safety and tolerability of 40 mg preoperative propranolol twice daily in patients undergoing surgery for pancreatic cancer. Tertiary: Evaluating the feasibility and implementation of the trial (using the APEASE framework). This will help identify barriers and enablers to a future larger study. Short-time propranolol treatment is considered safe with a mild and manageable safety-profile. Risk-management, mitigations and guidelines to ensure patient safety is included in the protocol. Since this clinical trial is exploratory in nature, no sample-size calculation is performed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Prior therapy
Cannot have received: neoadjuvant oncological treatment
Lab requirements
Kidney function
No kidney insufficiency, defined as eGFR < 20 ml/min
Liver function
No liver insufficiency defined as chronically high liver enzymes or known chronic liver disease (e.g., hepatitis, steatosis, cirrhosis)
Cardiac function
No chronic hypotension (systolic blood pressure < 100 mg Hg for women and < 110 mg Hg for men), no bradycardia (pulse < 50 bpm), no heart insufficiency with affected (< 50%) left ventricle ejection fraction (LVEF), no cor pulmonale, no cardiogenic shock, no severe peripheral circulatory disorders, no history of sick sinus syndrome or atrioventricular block
Chronic hypotension, bradycardia, heart insufficiency with affected (< 50 %) LVEF, kidney insufficiency (eGFR < 20 ml/min), liver insufficiency (chronically high liver enzymes or known chronic liver disease), cor pulmonale, cardiogenic shock, severe peripheral circulatory disorders
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify